BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 16697240)

  • 1. [SERMs for treatment of osteoporosis: state-of-the-art and perspectives].
    Legrand E; Hoppé E; Chappard D; Audran M
    Gynecol Obstet Fertil; 2006 May; 34(5):423-8. PubMed ID: 16697240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
    Lee WL; Chao HT; Cheng MH; Wang PH
    Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
    Shintani M
    Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?
    Sambrook P
    Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):975-81. PubMed ID: 16301191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective estrogen receptor modulators and postmenopausal health.
    Roe EB; Chiu KM; Arnaud CD
    Adv Intern Med; 2000; 45():259-78. PubMed ID: 10635051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Selective estrogen-receptor modulators (SERM's) in postmenopausal women].
    Hart W; Netelenbos JC
    Ned Tijdschr Geneeskd; 1999 Aug; 143(35):1771-6. PubMed ID: 10494328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Raloxifene (Celvista, Evista)].
    Body JJ; Sternon J
    Rev Med Brux; 2000 Feb; 21(1):35-41. PubMed ID: 10748686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Another selective estrogen-receptor modulator for osteoporosis.
    Becker C
    N Engl J Med; 2010 Feb; 362(8):752-4. PubMed ID: 20181977
    [No Abstract]   [Full Text] [Related]  

  • 9. [Raloxifene (Evista) in the treatment of postmenopausal osteoporosis--the profile of the patient].
    Kastelan D; Korsić M
    Reumatizam; 2005; 52(2):67-70. PubMed ID: 16689133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Selective estrogen receptor modulators (SERMs)].
    Matsumoto T
    Clin Calcium; 2006 Sep; 16(9):1520-25. PubMed ID: 16951478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raloxifene: new preparation. Not better than oestrogen.
    Prescrire Int; 1999 Dec; 8(44):165-7. PubMed ID: 11503811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of breast cancer using selective oestrogen receptor modulators (SERMs).
    Powles TJ
    Breast Cancer Res; 2006; 8(5):111. PubMed ID: 17049068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Additional effect of SERM: mammary gland].
    Kurebayashi J
    Clin Calcium; 2004 Oct; 14(10):47-51. PubMed ID: 15577131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preventing and treating osteoporosis: strategies at the millennium.
    Sherman S
    Ann N Y Acad Sci; 2001 Dec; 949():188-97. PubMed ID: 11795353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raloxifene use in clinical practice: efficacy and safety.
    Goldstein SR; Duvernoy CS; Calaf J; Adachi JD; Mershon JL; Dowsett SA; Agnusdei D; Stuenkel CA
    Menopause; 2009; 16(2):413-21. PubMed ID: 19092711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
    Maeda T; Ke HZ; Simmons H; Thompson D
    Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention and treatment of osteoporosis in women with breast cancer.
    Mincey BA; Moraghan TJ; Perez EA
    Mayo Clin Proc; 2000 Aug; 75(8):821-9. PubMed ID: 10943237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy.
    Johnell O; Cauley JA; Kulkarni PM; Wong M; Stock JL
    J Fam Pract; 2004 Oct; 53(10):789-96. PubMed ID: 15469774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raloxifene therapy in the reduction of fractures.
    Cefalu CA
    Am Fam Physician; 2000 Mar; 61(5):1272, 1275, 1279-80. PubMed ID: 10735336
    [No Abstract]   [Full Text] [Related]  

  • 20. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
    Ganz PA; Land SR
    Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.